Corporate and Regional Press Releases

Please find below a list of our press releases.

16 Jun 2017

ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17.

10 Jun 2017

New study shows IO Loop™ improves patient follow-up, engagement and satisfaction following treatment with TheraSphere®

Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period

22 May 2017

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

19 May 2017

BTG and HealthLoop collaborate on IO Loop™, an exclusive service to connect patients and interventional oncologists throughout treatment

Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology

20 Apr 2017

First European Patients Treated With DC Bead LUMI™ Radiopaque Drug-Eluting Beads

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of the first patients in the EU with DC Bead LUMI™.

7 Mar 2017

BTG announces CE Mark Certification for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead in the EU

DC Bead LUMI™ provides real-time visible, lasting confirmation of bead location during and post-embolisation of hypervascular tumours in the liver

27 Feb 2017

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS® Control Unit 4.0.

15 Feb 2017

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology

26 Jan 2017

New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), today announced the Canadian commercial launch of Varithena™ (polidocanol injectable foam), a drug/device combination product used to treat varicose veins.

26 Jan 2017

Nouveau traitement des varices offrant une intervention non chirurgicale à effraction minimale pour les Canadiens

BTG International Canada Inc., qui fait partie de BTG, une entreprise internationale de soins de santé spécialisés (LSE : BTG), a annoncé aujourd’hui le lancement sur le marché canadien de Varithena™ (mousse injectable à base de polidocanol), une combinaison de médicament et d’appareil utilisé pour traiter les varices.

About Us